|
Respirerx Pharmaceuticals Inc (RSPI) |
|
Respirerx Pharmaceuticals Inc
RSPI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Respirerx Pharmaceuticals Inc 's sales fell
in II. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -8.1 %
Respirerx Pharmaceuticals Inc net loss decreased from $-1 millions, to $-1 millions in II. Quarter 2023,
• More on RSPI's Growth
|
|
Respirerx Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 37.12 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on RSPI's Valuation
|
|
|
|
|
Respirerx Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 37.12 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on RSPI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com